What happened at the FDA panel?
On September 23, 2026, the FDA’s Molecular and Clinical Genetics Panel reviewed GRAIL’s premarket approval application for Galleri, a prescription blood test for screening adults aged 50 and older for multiple types of cancer. GRAIL filed the application on January 29, 2026. The test has held Breakthrough Device status since 2018.
The panel’s recommendation is advisory. The FDA is not bound by it. Still, it is the first time a multi-cancer early detection test has cleared this stage of federal review, and for employers it raises a question that will reach your desk before the 2028 plan year: should your health plan cover a blood test that screens for dozens of cancers at once?
According to GRAIL’s announcement of the panel results, ten voting members answered three questions:
| Question | Yes | No | Abstain |
|---|---|---|---|
| Is the test safe? | 10 | 0 | 0 |
| Is the test effective? | 6 | 4 | 0 |
| Do the benefits outweigh the risks? | 7 | 2 | 1 |
Why does the effectiveness split matter?
Safety was never seriously in doubt. A blood draw carries little physical risk. The effectiveness vote is the one to watch: four of ten panelists were not persuaded that the evidence shows the test works well enough, and several yes votes were openly tentative.
Panelists pushed back on the “early detection” label, pressed GRAIL on false positives, and raised the absence of evidence that the test reduces cancer deaths. They also warned that a negative result could give people a false sense of security. That split will shape how carriers, TPAs and stop-loss carriers read the eventual approval, and it should shape how you read it too.
How does a multi-cancer early detection test work?
Most cancer screenings look for one cancer at a time. A mammogram looks for breast cancer, and a colonoscopy looks for colorectal cancer. A multi-cancer early detection test analyzes one blood sample for signals that many different cancers leave behind.
Galleri uses next-generation sequencing to look for cancer-specific methylation patterns in cell-free DNA, the small fragments of genetic material that cells shed into the bloodstream. When it finds a cancer signal, it also predicts where in the body the signal likely came from, which helps a physician decide what imaging or testing to order next.
Two points matter for plan cost and for how you talk to members:
- A positive result is a signal, not a diagnosis. Every positive result leads to more workup: imaging, specialist visits and sometimes biopsies.
- A negative result does not rule out cancer.
It is easy to see why the idea resonates with employees. Many cancers have no recommended screening at all and are often found late, when treatment is harder and more expensive. That is exactly why you need a clear view of what the evidence supports today before members start asking HR why the plan does not cover it.
What does the clinical evidence show?
The panel reviewed data from two large studies in adults over 50: PATHFINDER 2 in North America and the NHS-Galleri trial in England. GRAIL presented PATHFINDER 2 results from 35,878 participants at the 2026 ASCO Annual Meeting:
| Measure | PATHFINDER 2 result | What it means |
|---|---|---|
| Specificity | 99.6% | Fewer than 0.4% of people without cancer got a false positive |
| Positive predictive value | 60.3% | Of 287 people with a cancer signal, 173 were diagnosed with cancer |
| Sensitivity, all cancers, 12 months | 39.3% | The test missed more cancers than it caught within a year |
| Sensitivity, 12 deadliest cancers | 69.8% | Stronger for the cancers behind about two-thirds of cancer deaths |
| Found at Stages I to III | 70.9% | Most newly detected cancers were found when curative treatment is more feasible |
| Time to diagnostic resolution | Median 48 days | 0.6% of participants needed an invasive procedure |
In plain terms, the test rarely raises a false alarm, and when it flags something, cancer is confirmed more often than not. The tradeoff is sensitivity, which is weaker for some common early-stage tumors.
The biggest open question is mortality. The National Cancer Institute says no definitive clinical trials have yet shown that multi-cancer detection tests reduce cancer deaths. Its Cancer Screening Research Network is enrolling up to 24,000 people in a Vanguard study to lay the groundwork for larger trials. NCI also recommends that standard screenings continue whether or not a person takes a multi-cancer test, and the FDA panel made the same point: this test is an add-on, never a replacement.
Who will pay for the test?
FDA approval is the gate every coverage decision now waits behind. Once it opens, Medicare, carriers and self-funded plans will each move on their own timeline.
Medicare. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act became law on February 3, 2026. Under the legislation, Medicare coverage can begin as early as 2028, subject to FDA approval and a CMS coverage determination. As the Prevent Cancer Foundation explains, the law also says coverage of existing screenings should not be affected. A National Coverage Determination will set eligibility, frequency and medical necessity criteria, and commercial carriers often take their cue from it.
Commercial plans. Today, the Galleri test lists for $949, and most health plans do not cover it. Approval alone will not change that. The ACA requires non-grandfathered plans to cover preventive services without cost sharing when they carry an A or B grade from the U.S. Preventive Services Task Force. Galleri has no USPSTF grade, so the mandate does not apply, even after approval. Coverage is a plan design choice, and for a self-funded employer, it is your choice.
What does it mean for your health plan?
Nothing changes for your plan today. But expect the question before your 2028 renewal, and you will be in a stronger position answering it with a documented strategy than reacting to a sales pitch.
Expect vendor outreach now. GRAIL and point solution vendors are likely to cite the panel vote. A favorable vote is not an approval, and the final FDA label may narrow what the test can claim. Hold any commitment until you see the approved labeling.
Model the full cost, not just the test. At $949 per test, screening 100 members aged 50 and older costs roughly $95,000 a year before a single follow-up. A complete model includes:
- expected test volume by age band and eligibility rules
- projected positive results and the diagnostic workup cost per result
- any savings tied to earlier-stage diagnosis, clearly labeled as assumptions
- plan document changes and member communication
Claims analytics on your own population is where that model starts.
Fully insured and self-funded plans move differently. A fully insured plan will follow the carrier’s medical policy once approval is final, with little room to move ahead of it. A self-funded plan decides on its own timeline. Carrier and TPA medical policies set a default, but you can cover the test, exclude it, or offer it outside the medical plan. Any change needs plan document and SPD updates, and your stop-loss carrier should be told.
What are your options beyond yes or no?
A self-funded plan has a middle ground once the FDA decides:
| Option | How it works | Watch for |
|---|---|---|
| Cover with criteria | Limit eligibility by age, cap frequency and require a physician order, mirroring whatever CMS adopts | Plan document and stop-loss language |
| Offer outside the medical plan | Make the test available through a navigation or screening program while the evidence matures | How follow-up care is paid |
| Cover with cost sharing | Apply a deductible or coinsurance, since the preventive care mandate does not apply | HSA plan rules and member experience |
| Wait for more data | Defer coverage until mortality evidence arrives | Write down why, so the decision is on the record |
Each option carries different plan document, stop-loss and communication work. The right answer depends on your population, your budget and how much evidence you want before you act.
How should you talk to members about it?
Member messaging carries real risk. If employees read “one blood test for 50 cancers” as a substitute for their colonoscopy, participation in screenings with proven benefit could drop. Every employee communication on the topic should make three points clear:
- The test does not replace mammograms, colonoscopies or other recommended screenings.
- A negative result does not rule out cancer.
- A positive result means more testing, not a diagnosis.
What should plan sponsors do before the decision?
Whatever you decide, decide through a documented process. Record the evidence you reviewed, the cost model, the options you weighed and why you chose your path. That record protects the plan and shows your people the decision was made in their interest. It is the same discipline behind every health plan renewal timeline. Seven steps to take now:
- Confirm whether your plan is self-funded or fully insured, and who sets coverage policy for new screenings.
- Ask your carrier or TPA how and when it will issue a medical policy on multi-cancer screening.
- Pull your census to estimate how many members are aged 50 and older.
- Build a cost model that includes follow-up care, not just the test price.
- Review your stop-loss contract for how new covered services are handled.
- Draft member communication language that protects participation in existing screenings.
- Set a decision date ahead of your 2028 renewal and document the process.
What should you ask before you cover it?
When a vendor, carrier or employee raises the topic, these questions separate strategy from sales:
- What does the final FDA label allow the test to claim, and what warnings does it carry?
- How many positive results should we expect in our population, and what will each workup cost?
- How will our TPA pay for follow-up imaging and biopsies after a positive result?
- Does our stop-loss carrier treat the test and its follow-up care as covered expenses?
- How will we measure whether the benefit is working for our members?
- How will we keep members on track with the screenings that already have proven benefit?
If the answers are unclear, that is useful information too. A benefit you cannot measure or explain to your people is a benefit worth waiting on. See how one employer used its own data to make plan decisions on the record in the Axiom Healthcare case study.
What should you watch next?
- The FDA decision on the premarket approval application.
- The approved label: whether the FDA allows “early detection” language, and what it requires about false negatives and follow-up testing.
- The CMS coverage process. A National Coverage Determination will likely become the benchmark commercial carriers follow.
- Carrier medical policies. National carriers and major TPAs will each take a position once approval is final.
- Competing tests. Other multi-cancer tests are in development and will follow the path Galleri sets.
This article is general information, not legal, tax or medical advice. It reflects the FDA review as of October 16, 2026.